Category «PHASE 3»

Nangibotide

Nangibotide LQEEDAGEYGCM-amide CAS 2014384-91-7 Molecular FormulaC54H82N14O22S2 Average mass1343.439 Da 2014384‐91‐7 L-Leucyl-L-glutaminyl-L-α-glutamyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl-L-methioninamide LR 12 peptide LQEEDAGEYG CM L-Leucyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl-L-methionine L-Methionine, L-leucyl-L-glutaminyl-L-glutaminyl-L-α-glutamyl-L-α-aspartyl-L-alanylglycyl-L-α-glutamyl-L-tyrosylglycyl-L-cysteinyl- нангиботид مانغيبوتيد 南吉博肽 Sequence (one letter code) LQEEDAGEYGCM-amide Sequence (three letter code) H-Leu-Gln-Glu-Glu-Asp-Ala-Gly-Glu-Tyr-Gly-Cys-Met-NH2 OriginatorInotrem ClassAnti-infectives; Anti-inflammatories; Anti-ischaemics; Antivirals; Peptides Mechanism of ActionTREML1 protein inhibitors Phase II/IIICOVID 2019 infections Phase IISeptic shock Phase IMyocardial infarction 12 Jul 2021Inotrem …

Rilzabrutinib

PRN 1008, Rilzabrutinib CAS 1575591-66-0 リルザブルチニブ; C36H40FN9O3, MW 665.7597 2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Anti-inflammatory disease, Autoimmune disease treatment Fda 2025, approvals 2025 8/29/2025, Wayrilz, To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids OriginatorPrincipia Biopharma Class2 ring heterocyclic compounds; Amines; Anti-inflammatories; Fluorobenzenes; Nitriles; Phenyl ethers; Piperazines; Piperidines; Pyrazoles; Pyrimidines; Skin disorder …

DEUCRAVACITINIB

DEUCRAVACITINIB BMS-986165 CAS 1609392-27-9, C20H22N8O3, 425.46 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide Tyk2-IN-4 UNII-N0A21N6RAU N0A21N6RAU GTPL10432 EX-A3154 BDBM50507816 NSC825520 s8879 OriginatorBristol-Myers Squibb ClassAmides; Aniline compounds; Anti-inflammatories; Antipsoriatics; Antirheumatics; Cyclopropanes; Ethers; Hepatoprotectants; Organic deuterium compounds; Pyridazines; Skin disorder therapies; Small molecules; Triazoles Mechanism of ActionTYK2 kinase inhibitors Phase IIIPlaque psoriasis Phase IICrohn’s disease; Lupus nephritis; Psoriatic arthritis; Systemic lupus erythematosus; Ulcerative colitis Phase …

Rezivertinib

BPI-7711, Rezivertinib 1835667-12-3 C27H30N6O3, 486.576 N-[2-[2-(dimethylamino)ethoxy]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Beta Pharma in collaboration Chinese licensee CSPC Pharmaceuticals Group , is developing BPI-7711 In June 2021, this drug was reported to be in phase 3 clinical development. APPROVALS 2024, CHINA 2024 OriginatorBeta Pharma ClassAmides; Amines; Antineoplastics; Indoles; Phenyl ethers; Pyrimidines; Small molecules Mechanism of ActionEpidermal growth factor receptor antagonists Phase …

Uprifosbuvir

Uprifosbuvir MK 3682, IDX 21437 ウプリホスブビル; Formula C22H29ClN3O9P CAS 1496551-77-9 Mol weight 545.9071 уприфосбувир [Russian] [INN] أوبريفوسبوفير [Arabic] [INN] 乌磷布韦 [Chinese] [INN] propan-2-yl (2R)-2-[[[(2R,3R,4R,5R)-4-chloro-5-(2,4-dioxopyrimidin-1-yl)-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate Isopropyl (2R)-2-{[(R)-{[(2R,3R,4R,5R)-4-chloro-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-3-hydroxy-4-methyltetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate IDX-21437, DB15206, SB18784, D10996, Q27281714 Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of Hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. It is currently in Phase III human clinical trials.[1][2][3] Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy …

OCID 5090, Enmetazobactam

OCID 5090 Enmetazobactam Beta-lactamase inhibitor. AAI-101 RN: 1001404-83-6 UNII: 80VUN7L00C Molecular Formula, C11-H14-N4-O5-S, Molecular Weight, 314.3206 (2S,3S,5R)-3-Methyl-3-((3-methyltriazol-3-ium-1-yl)methyl)-4,4,7-trioxo-4^6-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate 1H-1,2,3-Triazolium, 3-(((2S,3S,5R)-2-carboxy-3-methyl-4,4-dioxido-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-3-yl)methyl)-1-methyl-, inner salt Enmetazobactam The Board of directors of Orchid Pharma Ltd has announced that the company had developed a new molecule known as OCID-5090, which was licensed to a company named Allecra Therapeutics, this molecule was undergoing the clinical …

Sitravatinib

Sitravatinib 1-N‘-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 1-N’-[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide MG-91516 1,1-Cyclopropanedicarboxamide, N-[3-fluoro-4-[[2-[5-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-N’-(4- fluorophenyl)- N-(3-fluoro-4-((2-(5-(((2-methoxyethyl)amino)methyl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide シトラバチニブ; ситраватиниб , سيترافاتينيب , 司曲替尼 , Formula C33H29F2N5O4S Cas 1123837-84-2 Mol weight 629.6763 MG-516 Sitravatinib (MGCD516) UNII-CWG62Q1VTB CWG62Q1VTB MGCD-516 MGCD516 Antineoplastic, Receptor tyrosine kinase inhibitor Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib is being developed by Mirati Therapeutics.[1] Ongoing phase II …

NIROGACESTAT

NIROGACESTAT (2S)-2-[[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]amino]-N-[1-[1-(2,2-dimethylpropylamino)-2-methylpropan-2-yl]imidazol-4-yl]pentanamide 489.6 g/mol, C27H41F2N5O CAS 1290543-63-3 PF-03084014, 1290543-63-3, PF-3084014, 865773-15-5 QZ62892OFJ UNII:QZ62892OFJ UNII-QZ62892OFJ нирогацестат [Russian] [INN] نيروغاسيستات [Arabic] [INN] 尼罗司他 [Chinese] [INN] ニロガセスタット; orphan drug designation in June 2018 for the treatment of desmoid tumors, and with a fast track designation Nirogacestat, also known as PF-03084014, is a potent and selective gamma secretase (GS) inhibitor with potential antitumor activity. PF-03084014 binds to GS, blocking proteolytic …

TROFINETIDE

Trofinetide Molecular FormulaC13H21N3O6 Average mass315.322 Da Tofinetide , NNZ-2566 10076 853400-76-7 [RN] glycyl-2-methyl-L-prolyl-L-glutamic acid H-Gly-PMe-Glu-OH L-Glutamic acid, glycyl-2-methyl-L-prolyl- UNII-Z2ME8F52QL Z2ME8F52QL трофинетид [Russian] [INN] تروفينيتيد [Arabic] [INN] 曲非奈肽 [Chinese] [INN] IUPAC Condensed H-Gly-aMePro-Glu-OH Sequence GXE HELM PEPTIDE1{G.[*C(=O)[C@@]1(CCCN1*)C |$_R2;;;;;;;;_R1;$|].E}$$$$ IUPAC glycyl-alpha-methyl-L-prolyl-L-glutamic acid An (1-3) IGF-1 analog with neuroprotective activity. OPTICAL ROT; -52.4 ° Conc: 0.19 g/100mL; water ; 589.3 nm; Temp: 20 …

RIDINILAZOLE

RIDINILAZOLE SMT19969 Molecular FormulaC24H16N6 Average mass388.424 Da ридинилазол [Russian] [INN] ريدينيلازول [Arabic] [INN] 利地利唑 [Chinese] [INN] リジニラゾール; 10075 2,2′-Di(4-pyridinyl)-3H,3’H-5,5′-bibenzimidazole 308362-25-6 [RN] 6,6′-Bi-1H-benzimidazole, 2,2′-di-4-pyridinyl- Summit Therapeutics (formerly Summit Corp ) is developing ridinilazole the lead compound from oral narrow-spectrum, GI-restricted antibiotics, which also include SMT-21829, for the treatment of Clostridium difficile infection and prevention of recurrent disease. Ridinilazole (previously known as SMT19969) is an …